Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of BCR-ABL1 mutations, activation of additional pro-oncogenic pathways, and stem cell resistance. Drug combinations covering a broad range of targets may overcome resistance. CDDO-Me (bardoxolone...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Gleixner, Karoline V., Schneeweiss, Mathias, Eisenwort, Gregor, Berger, Daniela, Herrmann, Harald, Blatt, Katharina, Greiner, Georg, Byrgazov, Konstantin, Hoermann, Gregor, Konopleva, Marina, Waliul, Islam, Cumaraswamy, Abbarna A., Gunning, Patrick T., Maeda, Hiroshi, Moriggl, Richard, Deininger, Michael, Lion, Thomas, Andreeff, Michael, Valent, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685220/
https://ncbi.nlm.nih.gov/pubmed/28596283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.163436
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados